If it delivers, things may look up. An upgrade would be lovely. But a miss could make my portfolio look even messier. GSK is ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Importantly, 2025 will see further additions to GSK's portfolio with five new product approvals expected this year. At the forefront, our potential step changes in treatment with Blenrep or novel ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

GSK plans to buy back $2.50 billion in shares ... Write to Helena Smolak at [email protected] We sell different types of products and services to both investment professionals and individual ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

GSK expects its sales and profit to grow in ... We sell different types of products and services to both investment professionals and individual investors. These products and services are usually ...

GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

The company’s oncology portfolio, which had been facing ... or under regulatory review. This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in ...